Simcere Pharmaceutical Group Limited (stock code: 02096) reported its monthly return for the period ended 31 October 2025. According to the submission, the total number of issued ordinary shares remained at 2,595,697,618 with no treasury shares reported. The company confirmed that there were no movements in issued shares, and no share options, warrants, or convertible securities were exercised during the month.

Additionally, details revealed that a restricted share unit scheme amended and restated on 15 June 2023 allows for the potential issuance of up to 252,778,461 ordinary shares in the future. No changes to authorized share capital were noted, consistent with the framework for companies incorporated in Hong Kong under the Companies Ordinance (Cap. 622), where the concept of authorized share capital does not apply.